Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.

Seong Jin KimYao-Ting HuangJulia FoldiYeon Joo LeeMolly MaloySergio A GiraltAnn A JakubowskiGenovefa A Papanicolaou

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2018)

Nine percent of CMV R+, CD34+ -selected HCT recipients had resistant CMV by 1 year from HCT. Of 19 patients with resistant CMV, 58% had CMV end-organ disease and 42% died of CMV. Effective strategies for CMV prevention and restoration of CMV immunity are needed for CD34+ -selected HCT.

Keyphrases

bone marrow
cell cycle arrest
stem cells
nk cells
cell death